SOON-SHIONG PATRICK 4

What Happened Patrick Soon‑Shiong — Founder, Executive Chairman and Global Chief Scientific & Medical Officer of ImmunityBio (IBRX) and a reported 10% owner — had 274,122 restricted stock units (RSUs) vest on February 10, 2026 and converted those RSUs into common shares. No cash exercise price was required for the conversion (reported at $0.00). To cover tax withholding, 118,560 shares were withheld/treated as disposed at $6.93 per share, yielding approximately $821,621. Net new shares received by Soon‑Shiong were 155,562, worth roughly $1.08 million at the same price; the total market value of the vested RSUs was about $1.90 million.

Key Details

• Transaction date: February 10, 2026; Form 4 filed February 12, 2026 (timely within the typical 2‑business‑day window).
• Primary actions/codes: M = conversion/exercise of derivative (RSUs); F = shares withheld to satisfy tax liability.
• Shares involved: 274,122 RSUs converted; 118,560 shares withheld for taxes at $6.93/share (value $821,621); net issued to insider = 155,562 shares ($1.08M).
• Price basis: Withholding calculated using the issuer’s closing price on Feb 9, 2026 per footnote.
• Shares owned after transaction: not specified in the excerpt provided.
• Footnotes: RSUs represent contingent rights to receive common stock and vest per a schedule (vesting commencement Feb 10, 2025; vesting terms described in footnotes). Reporting person is a 10% owner with potential indirect holdings through multiple affiliated entities (see footnotes regarding NantWorks, NantBio, NantCapital, etc.).

Context This was not an open‑market sale or purchase but a routine RSU vesting and conversion with shares withheld to cover taxes (a common, non‑market cashless withholding). As a 10% owner with holdings through affiliated entities, the filing reflects both personal and affiliated interests; it does not by itself indicate a change in investment view.